Title : Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.

Pub. Date : 2019 Nov

PMID : 31392364






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes. siponimod cytochrome P450 family 3 subfamily A member 4 Homo sapiens
2 Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes. siponimod cytochrome P450 family 2 subfamily C member 9 Homo sapiens
3 PURPOSE: To evaluate the PK and safety of siponimod, a substrate of CYP2C9/3A4, in the presence or absence of a CYP3A4 inhibitor, itraconazole. siponimod cytochrome P450 family 2 subfamily C member 9 Homo sapiens